LivaNova LIVN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Business | ||||||
| Cardiopulmonary | $208.66M+18.3% | $206.58M+13.7% | $203.22M+18.0% | $199.27M+14.7% | $176.32M+13.1% | |
| Neuromodulation | $151.79M+9.3% | $152.72M+11.0% | $149.53M+6.9% | $151.67M+6.2% | $138.89M+3.8% | |
| Operating Income by Business | ||||||
| Cardiopulmonary | $30.07M+21.8% | $27.51M+32.0% | $24.7M+14.0% | $31.41M— | $24.69M— | |
| Neuromodulation | $44.15M-15.7% | $50.92M+15.0% | $56.19M+13.4% | $56.02M— | $52.35M— | |
| Total Assets by Business | ||||||
| Cardiopulmonary | $1.05B+11.3% | $1.05B+16.0% | $1.02B+5.4% | $1.01B+8.6% | $939.84M-0.4% | |
| Neuromodulation | $650.1M+1.3% | $639.74M-0.2% | $639.97M+0.7% | $637.72M-0.3% | $641.88M-1.5% | |
| Selling, general, and administrative by Business | ||||||
| Cardiopulmonary | $59.85M+2.3% | $56.71M-19.3% | $58.58M+18.7% | $56.01M+10.0% | $58.48M+15.2% | |
| Neuromodulation | $52.62M+10.6% | $53.99M+7.3% | $49.94M+9.7% | $51.1M+10.8% | $47.57M+4.1% | |
| Cost of Sales by Business | ||||||
| Cardiopulmonary | $100.93M+18.9% | $103.24M+14.1% | $98.09M+21.1% | $95.47M+10.2% | $84.92M+11.3% | |
| Neuromodulation | $14.22M+6.2% | $14.97M-8.3% | $12.69M+11.5% | $14.77M+21.0% | $13.39M+29.6% | |
| R&D by Business | ||||||
| Cardiopulmonary | $17.8M+47.7% | $19.12M+31.3% | $18.11M+44.2% | $16.47M+19.0% | $12.04M+0.8% | |
| Neuromodulation | $40.79M+59.5% | $32.85M+23.1% | $30.71M-8.1% | $29.78M+0.1% | $25.58M-17.9% | |
| Foreign currency adjustments by Business | ||||||
| Cardiopulmonary | -$7.25M-161% | —— | —— | $31.45M+677% | $11.91M+207% | |
| Neuromodulation | $0— | —— | $0— | $0— | $0— | |
| 3T litigation provision by Business | ||||||
| Cardiopulmonary | $15K-97.9% | $5K-99.8% | $3.74M-51.4% | -$77K-103% | $706K-89.0% | |
| Neuromodulation | $0— | $0— | $0— | $0— | $0— | |
| CapEx by Business | ||||||
| Cardiopulmonary | $10.41M+101% | $21.08M+123% | $9.5M+28.6% | $8.77M+16.5% | $5.17M+37.9% | |
| Neuromodulation | $8.84M+335% | $4.85M+160% | $4.74M+244% | $4.22M+482% | $2.03M+637% | |
| Goodwill by Business | ||||||
| Cardiopulmonary | $386.84M+6.5% | $394.09M+12.2% | $392.28M+2.5% | $394.61M+7.3% | $363.16M-2.7% | |
| Neuromodulation | $398.75M0.0% | $398.75M0.0% | $398.75M0.0% | $398.75M0.0% | $398.75M0.0% | |
| Net revenue by Geography | ||||||
| Europe | $75.65M+26.7% | $75.02M+21.7% | $67.68M+28.2% | $66.78M+30.3% | $59.7M+9.9% | |
| Rest of World | $101.93M+15.8% | $94.42M+10.9% | $99.62M+16.5% | $97.27M+10.8% | $87.99M+10.1% | |
| United States | $184.68M+9.2% | $191.49M+9.4% | $190.45M+5.9% | $188.47M+5.0% | $169.16M+5.3% | |
| Property, Plant and Equipment, Net by Geography | ||||||
| Europe | $152.89M+51.8% | $147.3M+56.1% | $129.27M+44.9% | $110.67M+31.7% | $100.7M+21.6% | |
| Rest of World | $16.19M+44.6% | $15.8M+47.7% | $14.94M+121% | $14.52M+147% | $11.2M+101% | |
| United States | $86.4M+31.3% | $79.5M+22.0% | $74.3M+1.3% | $70.23M+3.0% | $65.79M+3.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does LivaNova break its business down?
- LivaNova (LIVN) reports net revenue by business across 2 parts — Cardiopulmonary and Neuromodulation. Each is extracted from the segment footnotes and tracked over time.
- Where does LivaNova's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in LivaNova's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.